The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting
Primary Purpose
Glucose, High Blood
Status
Completed
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Control period
D-allulose period
Sponsored by

About this trial
This is an interventional treatment trial for Glucose, High Blood focused on measuring D-allulose, Ramadan fasting, Postprandial glucose, Continuous Glucose Monitoring
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes (Group 4 -low-risk group as defined by International Diabetes Federation ) - low-risk group is defined as a well-controlled diabetic patient treated with lifestyle modification and oral anti-diabetic medications
- The patient was diagnosed with type 2 diabetes before the previous Ramadan. They also had fasted during previous year of Ramadan (2020) and are planning to fast during the coming Ramadan (2021)
Exclusion Criteria:
- Patients with poor glycemic control; HbA1c of 8% or more
- Patients with other serious complications
- Pregnant, maternal, breastfeeding or pregnant women
- Patients with severe renal dysfunction (serum creatinine level of 1.5 mg/dl or higher)
- Patients who advised not to fast by doctor
- Patients participating in other clinical trials
- Patients with contraindications to D-allulose
Sites / Locations
- Universiti Putra Malaysia
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
14 days continuous glucose monitoring
Arm Description
The participants started and completed the control period for continuous 7 days and followed with D-allulose period for 7 days
Outcomes
Primary Outcome Measures
Postprandial glucose (mg/dl)
Evaluation on the effect of D-allulose on peak of postprandial glucose
the glucose levels were measured by flash continuous glucose monitoring system
Secondary Outcome Measures
% TIR
Percentage of time glucose in-target range generated by flash continuous glucose monitoring system
% TAR
Percentage of time glucose above-target range generated by flash continuous glucose monitoring system
% TBR
Percentage of time glucose below-target range generated by flash continuous glucose monitoring system
side-effects of D-allulose
Evaluate the side effects of D-allulose using a questionnaire [multiple choice answers]
Full Information
NCT ID
NCT05071950
First Posted
September 27, 2021
Last Updated
October 7, 2021
Sponsor
Universiti Putra Malaysia
Collaborators
Matsutani Chemical Industry Co., Ltd., Kagawa University
1. Study Identification
Unique Protocol Identification Number
NCT05071950
Brief Title
The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting
Official Title
The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
March 10, 2021 (Actual)
Primary Completion Date
June 30, 2021 (Actual)
Study Completion Date
June 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Putra Malaysia
Collaborators
Matsutani Chemical Industry Co., Ltd., Kagawa University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Postprandial hyperglycemia or rapid rise in blood glucose is defined as a blood glucose level>7.8 mmol/L (140 mg/dL) 1- 2 hours after consumption of food. It is associated to the development of diabetes among healthy individuals and a risk factor for the onset and progression of microvascular and macrovascular complications among diabetic patients. In Ramadan, postprandial hyperglycemia is often observed after the iftar (fasting break after sunset). The frequency of eating normally decreases during Ramadan, however, the energy intake remains questionable because dietary practices during Ramadan are influenced by local culture, economic status and individual dietary behaviors. In many Muslim societies including Malaysia, Ramadan has known as a month of feasting. Iftar meals are typically high calorie, carbohydrate-rich and usually sweet food resulting in rapid rise in glucose after the meal. This poses a challenge for the people with diabetes to manage their glucose level. D-allulose (a C-3 epimer of D-fructose) is a rare sugar and reported to have several health benefits, such as suppressing a rise in postprandial glucose levels. There is still a scarcity of research on patients with diabetes. As a result, the current clinical study sought to investigate the effect of supplemental D-allulose on participants with type 2 diabetes who consume real-meal calories during Ramadan iftar.
Detailed Description
D-allulose (a C-3 epimer of D-fructose) is one of the rare sugar types with zero calories, has 70 % sweetness as sucrose, and occur in a small quantities in nature. Extensive basic and clinical studies have reported beneficial outcomes to human health, includes improve hypoglycemia, reduced postprandial hyperglycemia, hypolipidemia, and antioxidant. D-allulose can be taken up to 0.5 g/kg daily will no side-effect on the human body. The U.S. Food and Drug Administration (FDA) has declared that D-allulose is Generally Recognized As Safe (GRAS) for use as a food ingredient and with other sweeteners. Previous clinical studies on D-allulose had shown an effective glucose suppressive effect after the meal, mostly in healthy individuals and pre-diabetics. There is still a scarcity of research on patients with diabetes. As a result, the current clinical study sought to investigate the effect of supplemental D-allulose on participants with type 2 diabetes who consume real-meal calories during Ramadan iftar (breaking fast at sunset). This was a non-randomized intervention study, which involved a single-arm group, and conducted during Muslim fasting month (Ramadan) between 13 April to 12 May 2021. The protocol required continuous 14 days of Ramadan and it was divided into two consecutive periods; began with first 7-day of control period and followed with a consecutive 7-day of D-allulose period. At the D-allulose period, 8.5g of D-allulose was consumed before the iftar meal. The FreeStyle Libre Pro Flash Glucose Monitory system (CFGM) was used to measure the glucose values.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glucose, High Blood
Keywords
D-allulose, Ramadan fasting, Postprandial glucose, Continuous Glucose Monitoring
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
14 days continuous glucose monitoring
Arm Type
Other
Arm Description
The participants started and completed the control period for continuous 7 days and followed with D-allulose period for 7 days
Intervention Type
Other
Intervention Name(s)
Control period
Intervention Description
first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)
participants did not allow to have added sugar/ sweetness drinks before the iftar meal
flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose
food diary was used to record the iftar meal
Intervention Type
Dietary Supplement
Intervention Name(s)
D-allulose period
Intervention Description
[started after 7 days of control period],
participants continued with D-allulose period for 7 days continuously
participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal
participants did not allow to have added sugar/ sweetness drinks before the iftar meal
flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose
food diary was used to record the iftar meal
a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose
Primary Outcome Measure Information:
Title
Postprandial glucose (mg/dl)
Description
Evaluation on the effect of D-allulose on peak of postprandial glucose
the glucose levels were measured by flash continuous glucose monitoring system
Time Frame
180 minutes
Secondary Outcome Measure Information:
Title
% TIR
Description
Percentage of time glucose in-target range generated by flash continuous glucose monitoring system
Time Frame
180 minutes
Title
% TAR
Description
Percentage of time glucose above-target range generated by flash continuous glucose monitoring system
Time Frame
180 minutes
Title
% TBR
Description
Percentage of time glucose below-target range generated by flash continuous glucose monitoring system
Time Frame
180 minutes
Title
side-effects of D-allulose
Description
Evaluate the side effects of D-allulose using a questionnaire [multiple choice answers]
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes (Group 4 -low-risk group as defined by International Diabetes Federation ) - low-risk group is defined as a well-controlled diabetic patient treated with lifestyle modification and oral anti-diabetic medications
The patient was diagnosed with type 2 diabetes before the previous Ramadan. They also had fasted during previous year of Ramadan (2020) and are planning to fast during the coming Ramadan (2021)
Exclusion Criteria:
Patients with poor glycemic control; HbA1c of 8% or more
Patients with other serious complications
Pregnant, maternal, breastfeeding or pregnant women
Patients with severe renal dysfunction (serum creatinine level of 1.5 mg/dl or higher)
Patients who advised not to fast by doctor
Patients participating in other clinical trials
Patients with contraindications to D-allulose
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Salimah Japar
Organizational Affiliation
Universiti Putra Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universiti Putra Malaysia
City
Serdang
State/Province
Selangor
ZIP/Postal Code
43400
Country
Malaysia
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35729673
Citation
Japar S, Fukunaga K, Kobayashi T, Imachi H, Sato S, Saheki T, Ibata T, Yoshimura T, Soh KL, Ong SL, Muhamed Z, Murao K. A pilot study on the effect of D-allulose on postprandial glucose levels in patients with type 2 diabetes mellitus during Ramadan fasting. Diabetol Metab Syndr. 2022 Jun 21;14(1):86. doi: 10.1186/s13098-022-00856-3.
Results Reference
derived
Learn more about this trial
The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting
We'll reach out to this number within 24 hrs